Inhibition of the transcription factor C/EBPβ causes both tumor cell death and macrophage repolarization, a unique combination of cytotoxic and immune-activating functions

C/EBPβ – a Development Stage Transcription Factor that Drives the Expression of:

  • Survivin (BIRC5), cIAP2 (BIRC3), Bcl family proteins: survival
  • Cyclins: proliferation
  • ID proteins: tumorigenesis
  • CD206, CD209: M2 macrophage polarization
  • IL-6: immune suppression

Lucicebtide MOA

ST101 MOA

Tumor

Sapience Tumor GIF

Tumor Microenvironment

Tumor Microenvironment

Ongoing Lucicebtide (ST101) Phase 1-2 Clinical Trial

Lucicebtide is currently in the Phase 2 portion of an ongoing Phase 1-2 monotherapy study in patients with recurrent GBM (rGBM). In a “window of opportunity” surgical sub-study of the Lucicebtide trial, Lucicebtide is being evaluated as a monotherapy in rGBM and in combination with radiation and temozolomide in newly diagnosed GBM (ndGBM).

Lucicebtide Clinical Trial